Table 1.
Baseline demographics and clinical characteristics
| Galcanezumab 120 mg
|
Galcanezumab 240 mg
|
Total | |||||
|---|---|---|---|---|---|---|---|
| Episodic migraine (N=109) | Chronic migraine (N=26) | Total (N=135) | Episodic migraine (N=104) | Chronic migraine (N=31) | Total (N=135) | ||
|
| |||||||
| Age in years, mean (SD) | 39.22 (11.53) | 44.35 (11.62) | 40.2 (11.7) | 43.87 (11.30) | 43.10 (10.04) | 43.7 (11.0)* | 42.0 (11.5) |
| Female, n (%) | 90 (82.57) | 20 (76.92) | 110 (81.5) | 86 (82.69) | 27 (87.10) | 113 (83.7) | 223 (82.6) |
| Race, n (%) | |||||||
| White | 82 (75.23) | 21 (80.77) | 103 (76.3) | 87 (83.65) | 21 (67.74) | 108 (80.0) | 211 (78.2) |
| Multiple | 20 (18.35) | 3 (11.54) | 23 (17.0) | 13 (12.50) | 6 (19.35) | 19 (14.1) | 42 (15.6) |
| Black | 5 (4.59) | 1 (3.85) | 6 (4.4) | 4 (3.85) | 4 (12.90) | 8 (5.9) | 14 (5.2) |
| Asian | 1 (0.92) | 1 (3.85) | 2 (1.5) | 0 | 0 | 0 | 2 (0.7) |
| Body mass index (kg/m2), mean (SD) | 26.42 (5.46) | 27.94 (5.95) | 26.55 (5.35) | 27.10 (4.90) | 24.90 (4.38) | 27.24 (5.75) | 26.9 (5.6) |
| MHDs per month, mean (SD) | 9.15 (5.16) | 12.12 (7.70) | 9.72 (5.82) | 10.38 (5.74) | 14.81 (8.46) | 11.40 (6.69)* | 10.56 (6.32) |
| Duration of migraine disease, years, mean (SD) | 20.43 (12.42) | 19.14 (12.30) | 20.2 (12.4) | 21.91 (12.31) | 19.16 (12.95) | 21.3 (12.5) | 20.7 (12.4) |
| Number of comorbidities, mean (SD) | 4.34 (3.23) | 4.08 (2.89) | 4.3 (3.2) | 4.43 (3.32) | 5.54 (3.73) | 4.7 (3.4) | 4.5 (3.3) |
| Prior preventive treatment, n (%) | 66 (60.55) | 15 (57.69) | 81 (60.0) | 63 (60.58) | 25 (80.65) | 88 (65.2) | 169 (62.6) |
| MIDAS total score, mean (SD) | 44.55 (41.85) | 51.08 (43.41) | 45.77 (42.06) | 50.85 (59.19) | 64.39 (67.64) | 53.96 (61.24) | 49.90 (52.66) |
| MSQ Role Function-Restrictive, mean (SD) | 47.94 (19.43) | 44.91 (18.04) | 47.37 (19.15) | 48.82 (18.54) | 43.78 (17.56) | 47.66 (18.38) | 47.52 (18.73) |
| PGI-S, mean (SD) | 4.64 (1.20) | 4.72 (1.24) | 4.65 (1.20) | 4.59 (1.21) | 4.87 (1.15) | 4.65 (1.20) | 4.65 (1.20) |
Note:
*
p<0.05 for differences between galcanezumab 240 mg vs 120 mg.
Abbreviations: MHD, migraine headache day; MIDAS, Migraine Disability Assessment; MSQ, Migraine-Specific Quality of Life Questionnaire; PGI-S, Patient Global Impression of Severity.